{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:01:01Z","timestamp":1785304861829,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.7759\/cureus.113553","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:18:57Z","timestamp":1785302337000},"source":"Crossref","is-referenced-by-count":0,"title":["Glycosylated Fibronectin in Fetal Growth Restriction: An Emerging Biomarker of Placental Dysfunction"],"prefix":"10.7759","author":[{"given":"Dimitrios I","family":"Karoutsos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stefanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Michala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Antsaklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Mavrogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Asimakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Daskalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.05.010","article-title":"Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal\u00a0growth restriction: (Replaces Clinical Guideline Number 3, April 2012)","volume":"223","author":"Martins JG","year":"2020","unstructured":"Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal\u00a0growth restriction: (Replaces Clinical Guideline Number 3, April 2012). Am J Obstet Gynecol. 2020, 223:B2-B17. 10.1016\/j.ajog.2020.05.010","journal-title":"Am J Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.22134","article-title":"ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction","volume":"56","author":"Lees CC","year":"2020","unstructured":"Lees CC, Stampalija T, Baschat A, et al.. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020, 56:298-312. 10.1002\/uog.22134","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/uog.15884","article-title":"Consensus definition of fetal growth restriction: a Delphi procedure","volume":"48","author":"Gordijn SJ","year":"2016","unstructured":"Gordijn SJ, Beune IM, Thilaganathan B, et al.. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016, 48:333-9. 10.1002\/uog.15884","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000357592","article-title":"Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol","volume":"36","author":"Figueras F","year":"2014","unstructured":"Figueras F, Gratac\u00f3s E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014, 36:86-98. 10.1159\/000357592","journal-title":"Fetal Diagn Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cppeds.2011.01.001","article-title":"Fetal origins of adult disease","volume":"41","author":"Calkins K","year":"2011","unstructured":"Calkins K, Devaskar SU. Fetal origins of adult disease. Curr Probl Pediatr Adolesc Health Care. 2011, 41:158-76. 10.1016\/j.cppeds.2011.01.001","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.11.577","article-title":"Pathophysiology of placental-derived fetal growth\u00a0restriction","volume":"218","author":"Burton GJ","year":"2018","unstructured":"Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth\u00a0restriction. Am J Obstet Gynecol. 2018, 218:S745-61. 10.1016\/j.ajog.2017.11.577","journal-title":"Am J Obstet Gynecol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13763","article-title":"Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome","volume":"75","author":"Stepan H","year":"2020","unstructured":"Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome. Hypertension. 2020, 75:918-26. 10.1161\/HYPERTENSIONAHA.119.13763","journal-title":"Hypertension"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-020-2809-2","article-title":"Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study","volume":"20","author":"Huhn EA","year":"2020","unstructured":"Huhn EA, Hoffmann I, Martinez De Tejada B, et al.. Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study. BMC Pregnancy Childbirth. 2020, 20:128. 10.1186\/s12884-020-2809-2","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16323","article-title":"Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study","volume":"127","author":"Nagalla SR","year":"2020","unstructured":"Nagalla SR, Janaki V, Vijayalakshmi AR, et al.. Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study. BJOG. 2020, 127:1687-94. 10.1111\/1471-0528.16323","journal-title":"BJOG"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-025-07243-6","article-title":"Glycosylated fibronectin in preeclampsia: a systematic review and meta-analysis","volume":"25","author":"Liao L","year":"2025","unstructured":"Liao L, Liu M, Yin Y, Xu Q, Yuan L, Xie S, Zhou R. Glycosylated fibronectin in preeclampsia: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2025, 25:228. 10.1186\/s12884-025-07243-6","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.preghy.2024.101177","article-title":"Glycosylated fibronectin as a biomarker for preeclampsia and preeclampsia-related complications","volume":"39","author":"Kluivers AC","year":"2025","unstructured":"Kluivers AC, Neuman RI, Kalra B, Kumar A, Visser W, Danser AH, Saleh L. Glycosylated fibronectin as a biomarker for preeclampsia and preeclampsia-related complications. Pregnancy Hypertens. 2025, 39:101177. 10.1016\/j.preghy.2024.101177","journal-title":"Pregnancy Hypertens"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.12.004","article-title":"Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy","volume":"218","author":"McCowan LM","year":"2018","unstructured":"McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am J Obstet Gynecol. 2018, 218:S855-68. 10.1016\/j.ajog.2017.12.004","journal-title":"Am J Obstet Gynecol"},{"key":"ref13","unstructured":"Servier Medical Art. (2026). Accessed. July 17, 2026: https:\/\/smart.servier.com\/."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/pd.4412","article-title":"Stage-based approach to the management of fetal growth restriction","volume":"34","author":"Figueras F","year":"2014","unstructured":"Figueras F, Gratacos E. Stage-based approach to the management of fetal growth restriction. Prenat Diagn. 2014, 34:655-9. 10.1002\/pd.4412","journal-title":"Prenat Diagn"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.08.009","article-title":"The \"great obstetrical syndromes\" are associated with disorders of deep placentation","volume":"204","author":"Brosens I","year":"2011","unstructured":"Brosens I, Pijnenborg R, Vercruysse L, Romero R. The \"great obstetrical syndromes\" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011, 204:193-201. 10.1016\/j.ajog.2010.08.009","journal-title":"Am J Obstet Gynecol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1111726","article-title":"Latest advances in understanding preeclampsia","volume":"308","author":"Redman CW","year":"2005","unstructured":"Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005, 308:1592-4. 10.1126\/science.1111726","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0225-CC","article-title":"Sampling and definitions of placental lesions: Amsterdam Placental Workshop Group Consensus Statement","volume":"140","author":"Khong TY","year":"2016","unstructured":"Khong TY, Mooney EE, Ariel I, et al.. Sampling and definitions of placental lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch Pathol Lab Med. 2016, 140:698-713. 10.5858\/arpa.2015-0225-CC","journal-title":"Arch Pathol Lab Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00372","article-title":"Endothelial dysfunction and preeclampsia: role of oxidative stress","volume":"5","author":"S\u00e1nchez-Aranguren LC","year":"2014","unstructured":"S\u00e1nchez-Aranguren LC, Prada CE, Ria\u00f1o-Medina CE, Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol. 2014, 5:372. 10.3389\/fphys.2014.00372","journal-title":"Front Physiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.102","article-title":"Pre-eclampsia part 1: current understanding of its pathophysiology","volume":"10","author":"Chaiworapongsa T","year":"2014","unstructured":"Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014, 10:466-80. 10.1038\/nrneph.2014.102","journal-title":"Nat Rev Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard SE","year":"2003","unstructured":"Maynard SE, Min JY, Merchan J, et al.. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003, 111:649-58. 10.1172\/JCI17189","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2016.07.011","article-title":"Fibronectin, the extracellular glue","volume":"60-61","author":"Zollinger AJ","year":"2017","unstructured":"Zollinger AJ, Smith ML. Fibronectin, the extracellular glue. Matrix Biol. 2017, 60-61:27-37. 10.1016\/j.matbio.2016.07.011","journal-title":"Matrix Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomimetics8020146","article-title":"The extracellular matrix: its composition, function, remodeling, and role in tumorigenesis","volume":"8","author":"Dzobo K","year":"2023","unstructured":"Dzobo K, Dandara C. The extracellular matrix: its composition, function, remodeling, and role in tumorigenesis. Biomimetics (Basel). 2023, 8:146. 10.3390\/biomimetics8020146","journal-title":"Biomimetics (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-018-02171-3","article-title":"A review of integrin-mediated endothelial cell phenotype in the design of cardiovascular devices","volume":"47","author":"Post A","year":"2019","unstructured":"Post A, Wang E, Cosgriff-Hernandez E. A review of integrin-mediated endothelial cell phenotype in the design of cardiovascular devices. Ann Biomed Eng. 2019, 47:366-80. 10.1007\/s10439-018-02171-3","journal-title":"Ann Biomed Eng"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220938741","article-title":"The role of extracellular matrix in normal and pathological pregnancy: future applications of microphysiological systems in reproductive medicine","volume":"245","author":"O'Connor BB","year":"2020","unstructured":"O'Connor BB, Pope BD, Peters MM, Ris-Stalpers C, Parker KK. The role of extracellular matrix in normal and pathological pregnancy: future applications of microphysiological systems in reproductive medicine. Exp Biol Med (Maywood). 2020, 245:1163-74. 10.1177\/1535370220938741","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-025-01348-5","article-title":"Extracellular matrix and pregnancy: functions and opportunities caught in the net","volume":"23","author":"Rossi F","year":"2025","unstructured":"Rossi F, Luppi S, Fejza A, Giolo E, Ricci G, Andreuzzi E. Extracellular matrix and pregnancy: functions and opportunities caught in the net. Reprod Biol Endocrinol. 2025, 23:24. 10.1186\/s12958-025-01348-5","journal-title":"Reprod Biol Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.150458","article-title":"Conformational remodeling of the fibronectin matrix selectively regulates VEGF signaling","volume":"127","author":"Ambesi A","year":"2014","unstructured":"Ambesi A, McKeown-Longo PJ. Conformational remodeling of the fibronectin matrix selectively regulates VEGF signaling. J Cell Sci. 2014, 127:3805-16. 10.1242\/jcs.150458","journal-title":"J Cell Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.304972","article-title":"Fibronectin induces endothelial cell migration through \u03b21 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653\/654 and 766","volume":"287","author":"Zou L","year":"2012","unstructured":"Zou L, Cao S, Kang N, Huebert RC, Shah VH. Fibronectin induces endothelial cell migration through \u03b21 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653\/654 and 766. J Biol Chem. 2012, 287:7190-202. 10.1074\/jbc.M111.304972","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.322332","article-title":"Integrin-dependent cell-matrix adhesion in endothelial health and disease","volume":"132","author":"Aman J","year":"2023","unstructured":"Aman J, Margadant C. Integrin-dependent cell-matrix adhesion in endothelial health and disease. Circ Res. 2023, 132:355-78. 10.1161\/CIRCRESAHA.122.322332","journal-title":"Circ Res"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.33574\/hjog.0530","article-title":"Glycosylated fibronectin as a wide-spectrum biomarker in pregnancy","volume":"22","author":"Karoutsos D","year":"2023","unstructured":"Karoutsos D, Fasoulakis Z, Michala S, Stefanidis K, Antsaklis P. Glycosylated fibronectin as a wide-spectrum biomarker in pregnancy. HJOG. 2023, 22:49-55.","journal-title":"HJOG"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2014.07.052","article-title":"Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia","volume":"212","author":"Rasanen J","year":"2015","unstructured":"Rasanen J, Quinn MJ, Laurie A, Bean E, Roberts CT Jr, Nagalla SR, Gravett MG. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol. 2015, 212:82.e1-9. 10.1016\/j.ajog.2014.07.052","journal-title":"Am J Obstet Gynecol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182a0c88b","article-title":"Glycosylated fibronectin as a first-trimester biomarker for prediction of gestational diabetes","volume":"122","author":"Rasanen JP","year":"2013","unstructured":"Rasanen JP, Snyder CK, Rao PV, et al.. Glycosylated fibronectin as a first-trimester biomarker for prediction of gestational diabetes. Obstet Gynecol. 2013, 122:586-94. 10.1097\/AOG.0b013e3182a0c88b","journal-title":"Obstet Gynecol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05670-8","article-title":"Glycosylated fibronectin as a first trimester marker for gestational diabetes","volume":"302","author":"Alanen J","year":"2020","unstructured":"Alanen J, Appelblom H, Korpimaki T, et al.. Glycosylated fibronectin as a first trimester marker for gestational diabetes. Arch Gynecol Obstet. 2020, 302:853-60. 10.1007\/s00404-020-05670-8","journal-title":"Arch Gynecol Obstet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1842_24","article-title":"Glycosylated fibronectin as a biomarker to predict gestational diabetes mellitus in the first trimester of pregnancy","volume":"14","author":"Lata I","year":"2025","unstructured":"Lata I, Kant K, Mishra P. Glycosylated fibronectin as a biomarker to predict gestational diabetes mellitus in the first trimester of pregnancy. J Family Med Prim Care. 2025, 14:2484-9. 10.4103\/jfmpc.jfmpc_1842_24","journal-title":"J Family Med Prim Care"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2025.2474674","article-title":"Clinical utility of a glycosylated fibronectin test (Lumella(TM)) for assessment of impending preeclampsia","volume":"38","author":"Di Renzo GC","year":"2025","unstructured":"Di Renzo GC, Arduini M, Bartha JL, et al.. Clinical utility of a glycosylated fibronectin test (Lumella(TM)) for assessment of impending preeclampsia. J Matern Fetal Neonatal Med. 2025, 38:2474674. 10.1080\/14767058.2025.2474674","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-025-07853-0","article-title":"Predictive value of glycosylated fibronectin (GlyFn)\/placenta growth factor (PlGF) ratio for high-risk pregnancies: a cohort study","volume":"25","author":"Wirawan W","year":"2025","unstructured":"Wirawan W, Krisnadi SR, Anwar AD, Nugrahani AD. Predictive value of glycosylated fibronectin (GlyFn)\/placenta growth factor (PlGF) ratio for high-risk pregnancies: a cohort study. BMC Pregnancy Childbirth. 2025, 25:770. 10.1186\/s12884-025-07853-0","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/uog.26032","article-title":"Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction","volume":"61","author":"Stepan H","year":"2023","unstructured":"Stepan H, Galindo A, Hund M, Schlembach D, Sillman J, Surbek D, Vatish M. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 2023, 61:168-80. 10.1002\/uog.26032","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2016.03.010","article-title":"Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction","volume":"42","author":"Benton SJ","year":"2016","unstructured":"Benton SJ, McCowan LM, Heazell AE, et al.. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016, 42:1-8. 10.1016\/j.placenta.2016.03.010","journal-title":"Placenta"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.70128","article-title":"Maternal sFlt-1\/PlGF ratio to distinguish pathological fetal growth restriction from constitutional smallness: systematic review","volume":"133","author":"Byrne Z","year":"2026","unstructured":"Byrne Z, Brennan S, Watson D, Rudd D, Kandasamy Y. Maternal sFlt-1\/PlGF ratio to distinguish pathological fetal growth restriction from constitutional smallness: systematic review. BJOG. 2026, 133:922-31. 10.1111\/1471-0528.70128","journal-title":"BJOG"},{"key":"ref39","article-title":"Low pregnancy-associated plasma protein A level in the first trimester","volume":"60","author":"Huynh L","year":"2014","unstructured":"Huynh L, Kingdom J, Akhtar S. Low pregnancy-associated plasma protein A level in the first trimester. Can Fam Physician. 2014, 60:899-903.","journal-title":"Can Fam Physician"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2024.102732","article-title":"First-trimester PlGF and PAPP-A and the risk of placenta-mediated complications: PREDICTION prospective study","volume":"47","author":"C\u00f4t\u00e9 ML","year":"2025","unstructured":"C\u00f4t\u00e9 ML, Gigu\u00e8re Y, Forest JC, et al.. First-trimester PlGF and PAPP-A and the risk of placenta-mediated complications: PREDICTION prospective study. J Obstet Gynaecol Can. 2025, 47:102732. 10.1016\/j.jogc.2024.102732","journal-title":"J Obstet Gynaecol Can"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62049-3","article-title":"2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial","volume":"385","author":"Lees CC","year":"2015","unstructured":"Lees CC, Marlow N, van Wassenaer-Leemhuis A, et al.. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015, 385:2162-72. 10.1016\/S0140-6736(14)62049-3","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517703-glycosylated-fibronectin-in-fetal-growth-restriction-an-emerging-biomarker-of-placental-dysfunction","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:18:58Z","timestamp":1785302338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517703-glycosylated-fibronectin-in-fetal-growth-restriction-an-emerging-biomarker-of-placental-dysfunction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.113553","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}